Fundam Clin Pharmacol (1990) 4, 547-558 0 Elsevier, Paris
541
Hemodynamic and cardiac effects of spiraprilat in normal and sodium depleted conscious dogs JL GCrard, E Pussard, A Berdeaux, JF Giudicelli* mpartement de Pharmacologie. Facult6 de M6decine Paris-Sud, 63, rue Gabriel-Pkri, 94276 Le Kremlin-Bicetre Cedex, France (Received 15 January 1990; accepted 8 March 1990)
Summary - The cardiac and hemodynamic effects of 3 doses (0.1,0.3 and 1 mg/kg, iv) of spiraprilat, the diacid active metabolite of the new angiotensin I converting enzyme inhibitor spirapril, have been investigated and compared to those of saline in chronically implanted conscious dogs at rest. Under a normal sodium diet, spiraprilat, 1 mg/kg, induced significant (at least P
541
Hemodynamic and cardiac effects of spiraprilat in normal and sodium depleted conscious dogs JL GCrard, E Pussard, A Berdeaux, JF Giudicelli* mpartement de Pharmacologie. Facult6 de M6decine Paris-Sud, 63, rue Gabriel-Pkri, 94276 Le Kremlin-Bicetre Cedex, France (Received 15 January 1990; accepted 8 March 1990)
Summary - The cardiac and hemodynamic effects of 3 doses (0.1,0.3 and 1 mg/kg, iv) of spiraprilat, the diacid active metabolite of the new angiotensin I converting enzyme inhibitor spirapril, have been investigated and compared to those of saline in chronically implanted conscious dogs at rest. Under a normal sodium diet, spiraprilat, 1 mg/kg, induced significant (at least P
